Project Grant R43HL170773
Award Date
9/15/23
Completion Date
9/14/24
Dollars Obligated
$298K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The federal Project Grant award R01HL175892, funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate new technology for accurate, rapid, point-of-care, and high-frequency blood gas analysis. The $735,939 award supports two key objectives: 1) creating a miniaturized and automated device that attaches to an arterial catheter to enable direct sampling and immediate blood gas analysis at the bedside,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test for measuring anti-Factor Xa activity and hemoglobin levels. This rapid diagnostic tool is intended to guide emergency management of bleeding and strokes in patients on anti-Xa direct oral anticoagulants. The grant aims to leverage the company's existing technology, including a...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
This $265,347 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc., a minority-owned small business in Detroit, Michigan. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system to assess red blood cell sickling under hypoxic conditions as an indicator of sickle cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,963 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New Health Sciences, Inc. (Hemanext Inc.) to evaluate the hemostatic function of platelets stored under hypoxic conditions for whole blood (WB) transfusion. The project aims to develop an improved WB storage platform that maintains an oxygen-managed environment to provide higher quality red blood cells for oxygen delivery and shock reversal, while...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $288,043 to Glycodots LLC to develop a rapid diagnostic test (EPX-RDT) that can detect eosinophil peroxidase (EPX) from nasal swab samples. The goal is to create a non-invasive, point-of-care tool to diagnose and manage asthma by measuring EPX, an important biomarker associated with...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Dynocardia, Inc. a $499,881 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to complete the verification and validation (V&V) of their production-grade Vitrack hospital device. Vitrack is a wrist-wearable, cuff-less device that utilizes proprietary optomechanical sensor and computer vision technology to provide accurate, continuous, and non-invasive blood pressure monitoring, overcoming...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $500,000 in funding to Aventusoft LLC, a small business located in Boca Raton, FL. The goal of this late-stage development project is to advance Aventusoft's non-invasive "HATS-OFF" heart failure monitoring technology towards commercialization. Specifically, the award will enable Aventusoft to: 1) Manufacture the HATS-OFF device with added ECG...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...